BioAtla Inc.

05/11/2022 | Press release | Distributed by Public on 05/11/2022 07:24

First Patients Dosed in Phase 2 Platform Clinical Trial Testing Novel Immunotherapy Combinations in Highly Malignant Ovarian Cancer